The recent emergence of targeted therapies, including antibody–drug conjugates, bispecific antibodies, and CD19 chimeric antigen receptor (CAR) T cell therapy, revolutionized B-lineage acute lymphoblastic leukemia (B-ALL) management, allowing certain optimism, at least for adult patients with Ph+ B-ALL, on gradually replacing chemotherapy and hematopoietic stem cell transplantation in the first remission. Here, CD19 is linked to acute lymphoblastic leukemia.